4D Molecular Therapeutics Inc (NASDAQ:FDMT) has a beta value of 2.74 and has seen 1.19 million shares traded in the last trading session. The company, currently valued at $346.71M, closed the last trade at $7.50 per share which meant it lost -$0.12 on the day or -1.57% during that session. The FDMT stock price is -383.33% off its 52-week high price of $36.25 and 2.4% above the 52-week low of $7.32. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.05 million shares traded. The 3-month trading volume is 867.75K shares.
The consensus among analysts is that 4D Molecular Therapeutics Inc (FDMT) is Buy stock at the moment, with a recommendation rating of 1.64. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 4 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight.
4D Molecular Therapeutics Inc (NASDAQ:FDMT) trade information
Sporting -1.57% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the FDMT stock price touched $7.50 or saw a rise of 16.29%. Year-to-date, 4D Molecular Therapeutics Inc shares have moved -62.98%, while the 5-day performance has seen it change -13.49%. Over the past 30 days, the shares of 4D Molecular Therapeutics Inc (NASDAQ:FDMT) have changed -12.49%. Short interest in the company has seen 8.18 million shares shorted with days to cover at 9.89.
Wall Street analysts have a consensus price target for the stock at $40, which means that the shares’ value could jump 81.25% from current levels. The projected low price target is $30.0 while the price target rests at a high of $58.0. In that case, then, we find that the current price level is -673.33% off the targeted high while a plunge would see the stock gain -300.0% from current levels.
4D Molecular Therapeutics Inc (FDMT) estimates and forecasts
Figures show that 4D Molecular Therapeutics Inc shares have underperformed across the wider relevant industry. The company’s shares have lost -68.70% over the past 6 months, with this year growth rate of -9.69%, compared to 16.70% for the industry.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -46.35% over the past 5 years.
FDMT Dividends
4D Molecular Therapeutics Inc is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
4D Molecular Therapeutics Inc (NASDAQ:FDMT)’s Major holders
Insiders own 3.91% of the company shares, while shares held by institutions stand at 115.28% with a share float percentage of 119.98%. Investors are also buoyed by the number of investors in a company, with 4D Molecular Therapeutics Inc having a total of 215.0 institutions that hold shares in the company. The top two institutional holders are RA CAPITAL MANAGEMENT, L.P. with over 5.1 million shares worth more than $107.01 million. As of 2024-06-30, RA CAPITAL MANAGEMENT, L.P. held 10.3471% of shares outstanding.
The other major institutional holder is BLACKROCK INC., with the holding of over 4.9 million shares as of 2024-06-30. The firm’s total holdings are worth over $102.79 million and represent 9.9385% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . As of Jun 30, 2024 , the former fund manager holds about 3.15% shares in the company for having 1.46 shares of worth $10.92 million while later fund manager owns 1.29 shares of worth $9.71 million as of Sep 30, 2024 , which makes it owner of about 2.80% of company’s outstanding stock.
